| abstract |
The compounds of the formula: wherein ring is a hetero ring containing nitrogen atom, optionally selected from n is 0-2; Y is bond or alkylene; Z is bond, alkylene or vinylene; E is (i) 4-15 membered, unsaturated, partially saturated or fully saturated, mono or bicyclic hetero ring containing as hetero atoms, 1 or 2 N atoms, 1 or 2 O atoms or 1 S atom, (ii) 4-15 membered, unsaturated or partially saturated, mono or bicyclic carbocyclic ring, or (iii) -OR4 (in which R4 is hydrogen atom, alkyl or alkyl substituted by a hydroxy group); Cyc is 5-7 membered, unsaturated, partially saturated or fully saturated, monocyclic hetero ring containing as hetero atoms, 1 or 2 N atoms or 5-7 membered, unsaturated or partially saturated, monocyclic carbocyclic ring; R1 is H or alkyl; R2 is H, alkyl, alkoxy or halogen atom; R3 is H, alkyl, alkoxy or -COOR5 (in which R5 is H or alkyl); with the proviso that (1) a Cyc ring should not bond to Z through a nitrogen atom in the Cyc ring when Z is vinylene and that (2) Y is not a single bond, when E is -OR4; or pharmaceutically acceptable acid addition salts thereof, pharmaceutically acceptable salts thereof, or hydrates thereof; have inhibitory effect on cGMP-PDE, or additionally on TXA2 synthetase. |